Literature DB >> 11739303

Comparison of use of medications after acute myocardial infarction in the Veterans Health Administration and Medicare.

L A Petersen1, S L Normand, L L Leape, B J McNeil.   

Abstract

BACKGROUND: There is concern that care provided in the Veterans Health Administration (VA) may be of poorer quality than non-VA health care. We compared use of medications after acute myocardial infarction in the VA with that in non-VA healthcare settings under fee-for-service (FFS) Medicare financing. METHODS AND
RESULTS: We used clinical data from 2486 VA and 29 249 FFS men >65 years old discharged with a confirmed diagnosis of acute myocardial infarction from 81 VA hospitals and 1530 non-VA hospitals. We reported odds ratios (ORs) for use of thrombolytics, beta-blockers, ACE inhibitors, or aspirin among ideal candidates adjusted for age, sample design (hospital academic affiliation, availability of cardiac procedures, and volume), and within-hospital clustering. Ideal VA candidates were more likely to undergo thrombolytic therapy at arrival (OR [VA relative to Medicare] 1.40 [1.05, 1.74]) or to receive ACE inhibitors (OR 1.67 [1.12, 2.45]) or aspirin (OR 2.32 [1.81, 3.01]) at discharge and equally likely to receive beta-blockers (OR 1.09 [1.03, 1.40]) at discharge.
CONCLUSIONS: Ideal candidates in VA were at least as likely as those in FFS to receive medical therapies of known benefit for acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739303     DOI: 10.1161/hc4901.100524

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Measuring the quality of the VA Health Care System.

Authors:  Paul A Heidenreich
Journal:  Health Serv Res       Date:  2004-12       Impact factor: 3.402

2.  Initial nontraumatic lower-extremity amputations among veterans with diabetes.

Authors:  Usha Sambamoorthi; Chin-Lin Tseng; Mangala Rajan; Tiwari Anjali; Patricia A Findley; Leonard Pogach
Journal:  Med Care       Date:  2006-08       Impact factor: 2.983

3.  The Veterans Health Administration: an American success story?

Authors:  Adam Oliver
Journal:  Milbank Q       Date:  2007       Impact factor: 4.911

4.  The Veterans Health Administration: a domestic model for a national health care system?

Authors:  Said A Ibrahim
Journal:  Am J Public Health       Date:  2007-10-30       Impact factor: 9.308

5.  Lack of health coverage among US veterans from 1987 to 2004.

Authors:  David U Himmelstein; Karen E Lasser; Danny McCormick; David H Bor; J Wesley Boyd; Steffie Woolhandler
Journal:  Am J Public Health       Date:  2007-10-30       Impact factor: 9.308

6.  The struggle for health equity: the sustained effort by the VA Healthcare System.

Authors:  Said A Ibrahim; Leonard E Egede; Uchenna S Uchendu; Michael J Fine
Journal:  Am J Public Health       Date:  2014-09       Impact factor: 9.308

7.  Long-term outcomes of regional variations in intensity of invasive vs medical management of Medicare Patients with acute myocardial infarction.

Authors:  Therese A Stukel; F Lee Lucas; David E Wennberg
Journal:  JAMA       Date:  2005-03-16       Impact factor: 56.272

8.  Effects of computerized guidelines for managing heart disease in primary care.

Authors:  William M Tierney; J Marc Overhage; Michael D Murray; Lisa E Harris; Xiao-Hua Zhou; George J Eckert; Faye E Smith; Nancy Nienaber; Clement J McDonald; Fredric D Wolinsky
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128

9.  Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus.

Authors:  Adeel A Butt; Joel Tsevat; Anthony C Leonard; Obaid S Shaikh; Deborah McMahon; Uzma A Khan; Zachariah Dorey-Stein; Vincent Lo Re
Journal:  Int J Infect Dis       Date:  2008-11-06       Impact factor: 3.623

10.  Mortality of Department of Veterans Affairs patients undergoing coronary revascularization in private sector hospitals.

Authors:  Mary S Vaughan-Sarrazin; Bonnie Wakefield; Gary E Rosenthal
Journal:  Health Serv Res       Date:  2007-10       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.